BioWorld

Nov. 3, 2006

XOMA, Takeda In Antibody Deal With $100M Potential

XOMA Ltd. could receive more than $100 million in a collaboration with Takeda Pharmaceutical Co. Ltd. to discover and develop monoclonal antibody therapeutics. (BioWorld Today) Read More

Exelixis' Stock Falls After XL999 Phase II Suspension

TopoTarget, LEO Deal Gives CuraGen Payoff For License

Gamida Cell Earns SPA To Begin Phase III For StemEx

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3

BioWorld

Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc....